139 related articles for article (PubMed ID: 25253976)
1. Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Kim HS; Kim JI; Jeong M; Seo JH; Kim IK; Cheung DY; Kim TJ; Kang CS
World J Gastroenterol; 2014 Sep; 20(35):12682-6. PubMed ID: 25253976
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
3. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Haas M; Ormanns S; Baechmann S; Remold A; Kruger S; Westphalen CB; Siveke JT; Wenzel P; Schlitter AM; Esposito I; Quietzsch D; Clemens MR; Kettner E; Laubender RP; Jung A; Kirchner T; Boeck S; Heinemann V
Br J Cancer; 2017 May; 116(11):1462-1469. PubMed ID: 28449008
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
5. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.
Oliveira-Cunha M; Hadfield KD; Siriwardena AK; Newman W
Pancreas; 2012 Apr; 41(3):428-34. PubMed ID: 22422135
[TBL] [Abstract][Full Text] [Related]
6. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
[TBL] [Abstract][Full Text] [Related]
7. Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-circulating DNA of pancreatic adenocarcinoma cases.
Wu J; Zhou Y; Zhang CY; Song BB; Wang BL; Pan BS; Lou WH; Guo W
Asian Pac J Cancer Prev; 2014; 15(24):10647-52. PubMed ID: 25605154
[TBL] [Abstract][Full Text] [Related]
8. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
[TBL] [Abstract][Full Text] [Related]
9. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.
Araki T; Shimizu K; Nakamura K; Nakamura T; Mitani Y; Obayashi K; Fujita Y; Kakegawa S; Miyamae Y; Kaira K; Ishidao T; Lezhava A; Hayashizaki Y; Takeyoshi I; Yamamoto K
J Mol Diagn; 2010 Jan; 12(1):118-24. PubMed ID: 20007840
[TBL] [Abstract][Full Text] [Related]
12. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
[TBL] [Abstract][Full Text] [Related]
13. Case report: composite pancreatic intraductal papillary mucinous neoplasm and neuroendocrine tumor: a new mixed neuroendocrine-non-neuroendocrine neoplasm?
Chen J; Wang P; Lv K; Zhou W
Diagn Pathol; 2021 Nov; 16(1):108. PubMed ID: 34801052
[TBL] [Abstract][Full Text] [Related]
14. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Brody JR; Witkiewicz AK; Yeo CJ
Adv Surg; 2011; 45():301-21. PubMed ID: 21954696
[No Abstract] [Full Text] [Related]
15. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
17. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
Däbritz J; Preston R; Hänfler J; Oettle H
Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
[No Abstract] [Full Text] [Related]
18. A Rare Pancreatic Tumor That Underwent a Change in Morphology and Histopathologic Features During Chemotherapy.
Seino S; Tsuchiya A; Natsui M
Gastroenterology; 2016 Feb; 150(2):e11-3. PubMed ID: 26718170
[No Abstract] [Full Text] [Related]
19. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
